Clinical Trials Logo

Pneumonia, Ventilator-Associated clinical trials

View clinical trials related to Pneumonia, Ventilator-Associated.

Filter by:

NCT ID: NCT00184925 Terminated - Pneumonia Clinical Trials

Ventilator Associated Pneumonia and Late Complications of Percutaneous Tracheostomy

Start date: October 2003
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate the incidence of ventilator associated pneumonia and late complications by comparing two different cannulas and two different percutaneous tracheostomy techniques.

NCT ID: NCT00148642 Completed - Respiratory Failure Clinical Trials

Silver-Coated Endotracheal Tube to Reduce Ventilator Associated Pneumonia (VAP)

NASCENT
Start date: November 2002
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if the use of a silver-coated endotracheal tube (ETT) can reduce the incidence and/or delay the time of onset of VAP when compared to a non silver-coated ETT in patients who have been mechanically ventilated for >= 24 hours.

NCT ID: NCT00118781 Terminated - Pneumonia Clinical Trials

Trial of Iseganan in Prevention of Ventilator-Associated Pneumonia

Start date: September 2003
Phase: Phase 2/Phase 3
Study type: Interventional

This is a multinational, double-blind, placebo-controlled trial designed to assess whether iseganan, applied topically to the oral cavity, can prevent ventilator-associated pneumonia among patients who are intubated and mechanically ventilated and survive for up to 14 days.

NCT ID: NCT00050401 Completed - Pneumonia Clinical Trials

Ventilator-Associated Pneumonia/Hospital-Acquired Pneumonia Requiring Mechanical Ventilatory Support

Start date: July 2002
Phase: Phase 3
Study type: Interventional

The purpose of the study is to find out if high dose antibiotic (meropenem, MERREM® I.V.), along with another drug called an aminoglycoside (a different type of antibiotic) is effective in decreasing or reducing the rate of antibiotic resistant Pseudomonas aeruginosa, Acinetobacter (germs that can cause pneumonia), and the rate of resistance in other difficult to treat germs which may cause hospital-acquired pneumonia requiring mechanical ventilatory support. The study hopes to show that by increasing the amount of meropenem administered and increasing the duration of infusion (release of the drug into the bloodstream), levels of the drug will stay at target levels in the bloodstream and decrease the ability of difficult to treat germs to resist, or not be killed by, the treatment using this antibiotic (meropenem) or other antibiotics.